|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
|
MX394360B
(es)
|
2013-03-14 |
2025-03-24 |
Sumitomo Pharma Oncology Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
MX387055B
(es)
|
2014-06-06 |
2025-03-19 |
Res Triangle Inst |
Agonistas del receptor de apelina (apj) y usos de los mismos.
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
JP2017528498A
(ja)
|
2014-09-25 |
2017-09-28 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
|
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
|
CA2976741C
(en)
|
2015-03-30 |
2023-01-17 |
Mission Therapeutics Limited |
1-cyano-pyrrolidine compounds as usp30 inhibitors
|
|
ES2898765T3
(es)
|
2015-04-10 |
2022-03-08 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituidos y métodos de uso de los mismos
|
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
|
AU2016258192B2
(en)
|
2015-05-06 |
2021-07-29 |
Leidos Biomedical Research, Inc. |
K-Ras modulators
|
|
US10463649B2
(en)
|
2015-06-08 |
2019-11-05 |
Texas Tech University System |
Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
EP3356351A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
*
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058805A1
(en)
*
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
WO2017100558A1
(en)
|
2015-12-09 |
2017-06-15 |
Research Triangle Institute |
Improved apelin receptor (apj) agonists and uses thereof
|
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
KR102444509B1
(ko)
*
|
2016-05-18 |
2022-09-19 |
미라티 테라퓨틱스, 인크. |
Kras g12c 억제제
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
JP2019532054A
(ja)
|
2016-09-20 |
2019-11-07 |
グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ |
Ｔｒｐｖ４拮抗薬
|
|
TW201825458A
(zh)
|
2016-09-20 |
2018-07-16 |
英商葛蘭素史克智慧財產（第二）有限公司 |
Ｔｒｐｖ４拮抗劑
|
|
RU2019110821A
(ru)
|
2016-09-20 |
2020-10-22 |
Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед |
Антагонисты trpv4
|
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3523289A1
(en)
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
KR20190095355A
(ko)
*
|
2016-12-15 |
2019-08-14 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암의 치료를 위한 조성물 및 방법
|
|
CN110366550A
(zh)
|
2016-12-22 |
2019-10-22 |
美国安进公司 |
作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
|
|
EP3558979B1
(en)
|
2016-12-22 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
|
|
JP7161760B2
(ja)
|
2017-02-03 |
2022-10-27 |
国立大学法人東北大学 |
複素環化合物
|
|
LT3483164T
(lt)
|
2017-03-20 |
2020-05-11 |
Forma Therapeutics, Inc. |
Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai
|
|
EP3612526A2
(en)
*
|
2017-04-20 |
2020-02-26 |
The Regents of the University of California |
K-ras modulators
|
|
AU2018273356B2
(en)
|
2017-05-22 |
2021-09-16 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
US10745385B2
(en)
|
2017-05-25 |
2020-08-18 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
CN110869357A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
化合物及其用于治疗癌症的使用方法
|
|
AU2018329920B2
(en)
|
2017-09-08 |
2022-12-01 |
Amgen Inc. |
Inhibitors of KRAS G12C and methods of using the same
|
|
WO2019084026A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
|
|
US10647715B2
(en)
|
2017-11-15 |
2020-05-12 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
LT3710439T
(lt)
|
2017-11-15 |
2023-05-10 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitoriai
|
|
HRP20230400T1
(hr)
|
2017-12-21 |
2023-06-23 |
Boehringer Ingelheim International Gmbh |
Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1
|
|
BR112020018094A2
(pt)
|
2018-03-08 |
2020-12-22 |
Incyte Corporation |
Compostos de aminopirazina diol como inibidores de pi3k-¿
|
|
KR20210003780A
(ko)
|
2018-04-05 |
2021-01-12 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Axl 키나제 억제제 및 그의 용도
|
|
WO2019204505A2
(en)
*
|
2018-04-18 |
2019-10-24 |
Theras, Inc. |
K-ras modulators with a vinyl sulfonamide moiety
|
|
CA3098574A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
EP3788053B1
(en)
|
2018-05-04 |
2024-07-10 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
MA52564A
(fr)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
|
US11096939B2
(en)
|
2018-06-01 |
2021-08-24 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
MX2020012204A
(es)
|
2018-06-11 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c para tratar el cáncer.
|
|
US11285156B2
(en)
|
2018-06-12 |
2022-03-29 |
Amgen Inc. |
Substituted piperazines as KRAS G12C inhibitors
|
|
US11046658B2
(en)
|
2018-07-02 |
2021-06-29 |
Incyte Corporation |
Aminopyrazine derivatives as PI3K-γ inhibitors
|
|
AU2019310590A1
(en)
|
2018-07-26 |
2021-01-14 |
Sumitomo Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
|
EA202190749A1
(ru)
|
2018-09-10 |
2021-07-09 |
Мирати Терапьютикс, Инк. |
Способы комбинированной терапии
|
|
JP2022500385A
(ja)
|
2018-09-10 |
2022-01-04 |
ミラティ セラピューティクス， インコーポレイテッド |
組み合わせ療法
|
|
EP3849537B1
(en)
|
2018-09-10 |
2024-10-23 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
EP3849535A4
(en)
|
2018-09-10 |
2022-06-29 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
EP3852791B1
(en)
|
2018-09-19 |
2024-07-03 |
Novo Nordisk Health Care AG |
Activating pyruvate kinase r
|
|
EP3853206B1
(en)
|
2018-09-19 |
2024-04-10 |
Novo Nordisk Health Care AG |
Treating sickle cell disease with a pyruvate kinase r activating compound
|
|
EP3628664A1
(en)
|
2018-09-25 |
2020-04-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Irreversible inhibitors of kras g12c mutant
|
|
CN113207291A
(zh)
*
|
2018-10-24 |
2021-08-03 |
亚瑞克西斯制药公司 |
2-(2-丙烯酰基-2,6-二氮杂螺[3.4]辛-6-基)-6-(1h-吲唑-4-基)苄腈衍生物及相关化合物作为用于抑制肿瘤转移的g12c突变kras蛋白的抑制剂
|
|
WO2020085504A1
(ja)
*
|
2018-10-26 |
2020-04-30 |
大鵬薬品工業株式会社 |
光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
|
|
JP7516029B2
(ja)
*
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
JP7377679B2
(ja)
*
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
AU2019384118B2
(en)
*
|
2018-11-19 |
2025-06-12 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
MX2021002804A
(es)
|
2018-12-05 |
2021-07-15 |
Mirati Therapeutics Inc |
Terapias de combinacion.
|
|
EP3908283A4
(en)
|
2019-01-10 |
2022-10-12 |
Mirati Therapeutics, Inc. |
KRAS G12C INHIBITORS
|
|
CN109646680B
(zh)
*
|
2019-01-31 |
2020-02-11 |
四川大学华西医院 |
一种治疗kras突变型肠癌的联合用药物
|
|
US20220152026A1
(en)
|
2019-02-12 |
2022-05-19 |
Novartis Ag |
Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
|
|
WO2020173935A1
(en)
|
2019-02-26 |
2020-09-03 |
Boehringer Ingelheim International Gmbh |
New isoindolinone substituted indoles and derivatives as ras inhibitors
|
|
KR102934231B1
(ko)
|
2019-03-05 |
2026-03-06 |
아스트라제네카 아베 |
항암제로 유용한 융합 삼환식 화합물
|
|
CN111662232B
(zh)
*
|
2019-03-06 |
2022-08-02 |
中国科学院上海药物研究所 |
具有2h-吲唑结构的小分子化合物及其合成和应用
|
|
MA55556A
(fr)
|
2019-04-02 |
2022-02-09 |
Aligos Therapeutics Inc |
Composés ciblant prmt5
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
WO2020234103A1
(en)
|
2019-05-21 |
2020-11-26 |
Bayer Aktiengesellschaft |
Identification and use of kras inhibitors
|
|
WO2020236947A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
|
CN113396147B
(zh)
*
|
2019-05-31 |
2024-06-18 |
上海翰森生物医药科技有限公司 |
芳香杂环类衍生物调节剂、其制备方法和应用
|
|
US12421236B2
(en)
|
2019-06-25 |
2025-09-23 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
|
|
MX2022002465A
(es)
|
2019-08-29 |
2022-05-19 |
Mirati Therapeutics Inc |
Inhibidores de kras g12d.
|
|
HRP20251148T1
(hr)
|
2019-09-19 |
2025-11-21 |
Novo Nordisk Health Care Ag |
Pripravci koji aktiviraju piruvat-kinazu r (pkr)
|
|
WO2021061749A1
(en)
|
2019-09-24 |
2021-04-01 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
CN112225734B
(zh)
*
|
2019-10-25 |
2021-12-07 |
南京瑞捷医药科技有限公司 |
Kras g12c抑制剂及其用途
|
|
UA129778C2
(uk)
|
2019-10-28 |
2025-07-30 |
Мерк Шарп Енд Доум Елелсі |
Низькомолекулярні інгібітори g12c-мутантного kras
|
|
US20230023023A1
(en)
|
2019-10-31 |
2023-01-26 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
TW202132316A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
AU2020377925A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
IL322454A
(en)
|
2019-11-04 |
2025-09-01 |
Revolution Medicines Inc |
ras inhibitors
|
|
CN110698378B
(zh)
*
|
2019-11-19 |
2021-03-19 |
上海皓元生物医药科技有限公司 |
2-(羟基-(甲基环丙基)苯基氨基)-1-哌嗪基乙酮衍生物的制备方法
|
|
BR112022009881A2
(pt)
*
|
2019-11-22 |
2022-10-11 |
Univ California |
Inibidores de caspase 6 e usos dos mesmos
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
PH12022551513A1
(en)
|
2019-12-20 |
2023-04-24 |
Mirati Therapeutics Inc |
Sos1 inhibitors
|
|
WO2021120890A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Pyrazolyl derivatives useful as anti-cancer agents
|
|
CN113045565A
(zh)
*
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
|
WO2021215545A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
|
WO2021215544A1
(en)
*
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
CN115135636B
(zh)
*
|
2020-04-29 |
2024-08-23 |
北京泰德制药股份有限公司 |
喹喔啉酮衍生物作为kras g12c突变蛋白的不可逆抑制剂
|
|
TW202210633A
(zh)
|
2020-06-05 |
2022-03-16 |
法商昂席歐公司 |
用於治療癌症之dbait分子與kras抑制劑的組合
|
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
|
US20250195521A1
(en)
|
2020-09-03 |
2025-06-19 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
EP4210833A4
(en)
|
2020-09-11 |
2024-09-11 |
Mirati Therapeutics, Inc. |
CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
|
|
CA3194067A1
(en)
|
2020-09-15 |
2022-03-24 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
JP2023544450A
(ja)
|
2020-09-23 |
2023-10-23 |
エラスカ・インコーポレイテッド |
三環式ピリドン及びピリミドン
|
|
CN114249703B
(zh)
*
|
2020-09-25 |
2023-10-13 |
四川科瑞德制药股份有限公司 |
适合工业放大的医药中间体的制备方法
|
|
JP2023553492A
(ja)
|
2020-12-15 |
2023-12-21 |
ミラティ セラピューティクス， インコーポレイテッド |
アザキナゾリン汎ＫＲａｓ阻害剤
|
|
EP4262803A4
(en)
|
2020-12-16 |
2025-03-12 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
US20240100172A1
(en)
|
2020-12-21 |
2024-03-28 |
Hangzhou Jijing Pharmaceutical Technology Limited |
Methods and compounds for targeted autophagy
|
|
JP7849366B2
(ja)
|
2020-12-22 |
2026-04-21 |
キル・レガー・セラピューティクス・インコーポレーテッド |
Ｓｏｓ１阻害剤およびその使用
|
|
US12128035B2
(en)
|
2021-03-19 |
2024-10-29 |
Novo Nordisk Health Care Ag |
Activating pyruvate kinase R
|
|
US20240246968A1
(en)
|
2021-04-27 |
2024-07-25 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras g12c mutant
|
|
TW202309052A
(zh)
|
2021-05-05 |
2023-03-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
KR20240017811A
(ko)
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
|
|
EP4359081A1
(en)
|
2021-06-23 |
2024-05-01 |
Novartis AG |
Pyrazolyl derivatives as inhibitors of the kras mutant protein
|
|
IL310291A
(en)
|
2021-07-23 |
2024-03-01 |
Theras Inc |
Compositions and methods for inhibition of ras
|
|
KR20240055778A
(ko)
|
2021-09-01 |
2024-04-29 |
노파르티스 아게 |
Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
CN113956233B
(zh)
*
|
2021-10-22 |
2023-06-06 |
南方医科大学 |
一种酰胺类化合物或其药学上可接受的盐及其制备方法和应用
|
|
MX2024004846A
(es)
|
2021-10-22 |
2024-05-03 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo.
|
|
CN114380682A
(zh)
*
|
2021-10-27 |
2022-04-22 |
上海毕得医药科技股份有限公司 |
一种2,3-二氟-4-甲氧基苯乙酸合成方法
|
|
CN119212994A
(zh)
|
2021-12-17 |
2024-12-27 |
建新公司 |
作为shp2抑制剂的吡唑并吡嗪化合物
|
|
WO2023152255A1
(en)
|
2022-02-10 |
2023-08-17 |
Bayer Aktiengesellschaft |
Fused pyrimidines as kras inhibitors
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
WO2023199180A1
(en)
|
2022-04-11 |
2023-10-19 |
Novartis Ag |
Therapeutic uses of a krasg12c inhibitor
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
CN120659773A
(zh)
|
2022-11-09 |
2025-09-16 |
锐新医药公司 |
化合物、复合物以及其制备方法和用途
|
|
WO2024182447A1
(en)
*
|
2023-02-28 |
2024-09-06 |
Vividion Therapeutics, Inc. |
Compounds and methods for modulating ras-pi3k
|
|
WO2024201691A1
(ja)
|
2023-03-28 |
2024-10-03 |
国立大学法人東北大学 |
オートファジーを誘導する化合物のスクリーニング方法
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
CR20250420A
(es)
|
2023-04-07 |
2025-11-20 |
Revolution Medicines Inc |
Inhibidores macrocíclicos de ras
|
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CN121464140A
(zh)
|
2023-04-14 |
2026-02-03 |
锐新医药公司 |
Ras抑制剂的结晶形式、含有其的组合物及其使用方法
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
EP4721766A1
(en)
|
2023-06-02 |
2026-04-08 |
Daiichi Sankyo Company, Limited |
Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor
|
|
GB2631397A
(en)
|
2023-06-28 |
2025-01-08 |
Sevenless Therapeutics Ltd |
New treatments for pain
|
|
WO2025016899A1
(en)
|
2023-07-19 |
2025-01-23 |
Bayer Aktiengesellschaft |
Spirocyclic compounds for the treatment of cancer
|
|
WO2025026903A1
(en)
|
2023-07-31 |
2025-02-06 |
Bayer Aktiengesellschaft |
Imidazo pyrimidine compounds for the treatment of cancer
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
GB2633813A
(en)
|
2023-09-21 |
2025-03-26 |
Sevenless Therapeutics Ltd |
New treatments for pain
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2025083426A1
(en)
|
2023-10-20 |
2025-04-24 |
Sevenless Therapeutics Limited |
New treatments for pain
|
|
AU2024361909A1
(en)
|
2023-10-20 |
2026-03-26 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
TW202542151A
(zh)
|
2023-12-22 |
2025-11-01 |
美商銳格醫藥有限公司 |
Ｓｏｓ１抑制劑及其用途
|
|
WO2025146548A1
(en)
|
2024-01-04 |
2025-07-10 |
Sevenless Therapeutics Limited |
Sos1 inhibitors useful to treat pain and cancer
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026035945A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
|
|
WO2026035947A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026064527A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
|
|
WO2026064520A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
|
|
CN119039303A
(zh)
*
|
2024-09-20 |
2024-11-29 |
上海信诺维生物医药有限公司 |
一种螺环化合物
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|